What are you searching for?

Sign in

Masimo and Cleveland Clinic Collaborate to Improve Hospital Remote Care

The collaboration will include joint development initiatives on predictive analytics and AI-based algorithms for improving cardiac care.

By: Michael Barbella

Managing Editor, Rodman Media

Masimo is partnering with Cleveland Clinic on hospital-based remote patient monitoring (RPM), integrating the latter’s critical care (eHospital) and non-critical care (eCMU) central patient monitoring platforms with the former’s Hospital Automation platform. The pair aims to provide telecritical care tools for clinicians that offer enhanced situational awareness and clinical decision-support for hospitalized patients, including the critically ill.

The collaboration will include joint development initiatives on predictive analytics and artificial intelligence (AI)-based algorithms for improving cardiac care.

“We are truly honored to have the opportunity to partner with Cleveland Clinic to advance patient care. By harnessing Masimo’s AI-powered decision support tools, automation solutions, and monitoring devices, alongside Cleveland Clinic’s vast clinical expertise and dedication to providing the highest quality, most innovative care, our partnership has the potential to significantly ease staff shortages, better standardize care, and promote intensivist- and specialist-led care,” Masimo Founder/CEO Joe Kiani said. “Ultimately, we will make significant strides in shifting from reactive to predictive and proactive care—improving patient outcomes, safety, and quality of care across the board.”

Cleveland Clinic’s existing critical care and non-critical care central monitoring platform provides continuous monitoring of various vital signs, including ECG, for both ICU and non-ICU patients at more than a 2,000-bed capacity. Its hospital-based RPM programs serve 11 hospitals, providing intensivist monitoring, 24/7 critical care nursing, and patient management. Cleveland Clinic’s programs1 have reduced patient mortality and reduced ICU length of stay while increasing caregiver satisfaction, according to the organization.2 With this partnership, Masimo and Cleveland Clinic will strive to bring these innovations and patient benefits to other healthcare systems in the future. The enhanced program is intended to increase awareness and facilitate triage with proactive responses to changes in a patient’s condition. This improves patient care and saves lives by ensuring the highest risk patients are identified and receive timely treatment while maintaining quality of care for all patients.1,2

“We see great opportunities to enhance remote care, particularly for critically ill individuals,” said Chiedozie Udeh, M.D., medical director of ICU Operations at Cleveland Clinic. “By combining our technical and clinical expertise, we aim to improve situational awareness for clinicians and continue to improve outcomes for patients.”

The Masimo Hospital Automation platform offers technologies designed to help clinicians improve patient care at the bedside, across the care continuum. Masimo Hospital Automation includes monitoring and wearable technologies, high-fidelity medical device integration, system-wide applications for surveillance and data visualization, and AI capabilities that support intelligent patient prioritization and help clinicians identify changes in patients’ condition more efficiently.

These decision-support tools are integrated into the Masimo Hospital Automation platform and utilize the Halo engine, technology which identifies deterioration patterns in multiple physiological parameters simultaneously, in real time. The Halo tools include Halo ION, a comprehensive, scalable, and customizable continuous early warning score to help streamline patient assessment and clinical workflows. As part of their work together, Masimo and Cleveland Clinic are partnering to jointly develop an additional Halo-based decision-support tool to support clinicians with earlier detection of adverse events—ultimately helping them manage and improve patient outcomes more effectively, for low-, mid-, and high-acuity patients.

“We look forward to exploring the effects of next-gen inpatient wearables, and as the capabilities of AI continue to advance, studying the potential impact on the care of cardiac patients, including those undergoing cardiac surgery,” added Thomas Callahan, M.D., staff cardiologist at Cleveland Clinic’s Heart, Vascular & Thoracic Institute, and principal investigator for the AI study.

Masimo is a global medical technology company that develops and produces various monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. Its mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, introduced in 1995, has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET is estimated to be used on more than 200 million patients in hospitals and other healthcare settings worldwide,10 and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing.11 In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi (rainbow PVi), and Oxygen Reserve Index (ORi). In 2013, Masimo introduced the Root Patient Monitoring and Connectivity Platform, built to be flexible and expandable to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine Brain Function Monitoring, O3 Regional Oximetry, and ISA Capnography with NomoLine sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters includes devices designed for use in various clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7, Radius PPG, and Radius VSM, portable devices like Rad-67, fingertip pulse oximeters like MightySat Rx, and devices available for use both in the hospital and at home, such as Rad-97 and the Masimo W1 Medical Watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet. Its portfolio of health and wellness solutions includes Radius Tº and Masimo W1 Sport. 

RPVi has not received U.S. Food and Drug Administration 510(k) clearance and is not available for sale in the United States.

References
1 Cantillon et al JAMA 15-10101. Issued August 2016.
2 Udeh C, Canfield C, Brown A et al. ICU Telemedicine and Clinical Factors Related to 30-Day Mortality: A Retrospective Cohort Study, Critical Care Medicine. January 2021 – Volume 49 – Issue 1 – p 9 doi: 10.1097/01.ccm.0000726092.34718.60.
3 Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
4 Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
5 de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
6 Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
7 Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
8 McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
9 McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
10 Estimate: Masimo data on file.
11 https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states

 

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics